Cytokines and 90Y-Radioembolization: Relation to Liver Function and Overall Survival

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cardiovascular and Interventional Radiology

• Publication date

  2017-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00270-017-1622-4PMID 28283704
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system

  2016cited by this paper
• SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

  2016cited by this paper
• Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

  2016cited by this paper
• Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

  2015influential reference
• Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: potential mechanism.

  2014influential reference
• Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity

  2014cited by this paper
• Prognostic factors and prevention of radioembolization‐induced liver disease

  2013influential reference
• Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.

  2013cited by this paper
• Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.

  2012cited by this paper
• Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal Metastases

  2012cited by this paper
• Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach

  2012cited by this paper
• Use of plasma angiogenesis-related factors to investigate the association of interleukin 8 and interleukin 6 levels with efficacy of sorafenib-based antiangiogenic therapy in patients with advanced hepatocellular carcinoma (HCC).

  2011cited by this paper
• Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation

  2011cited by this paper
• Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

  2010cited by this paper
• Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.

  2010cited by this paper
• Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases

  2010cited by this paper
• Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival

  2010cited by this paper
• Serum interleukin-6 levels in colorectal cancer patients—a summary of published results

  2010cited by this paper
• Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer

  2009cited by this paper
• Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.

  2009cited by this paper
• Liver disease induced by radioembolization of liver tumors

  2008cited by this paper
• Significance of interleukin-6 (IL-6) in breast cancer (review)

  2007cited by this paper
• Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study

  2005cited by this paper
• Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications.

  2005cited by this paper
• Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.

  2004cited by this paper
• Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer

  2003cited by this paper
• Significance of inflammatory cytokines in the progression of colorectal cancer.

  2003cited by this paper
• A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation

  2002cited by this paper
• Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with (90)Yttrium microspheres.

  2001cited by this paper
• Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.

  1999influential reference
• Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.

  1998cited by this paper
• Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation

  1998cited by this paper
• Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.

  1996cited by this paper
• Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.

  1996cited by this paper

• Can Cancer Cell Line In Vitro Radioembolization Model Help to Understand How Beta Radiation Affects Liver Tumor and Improve Treatment Results?

  2026cites this paper
• TARE-Induced Pan-Immune Inflammation Value as a Prognostic Biomarker in Liver-Dominant Metastatic Colorectal Cancer

  2025cites this paper
• Impact of IL-8 on survival after TARE in HCC: a comprehensive investigation and external validation from the SORAMIC trial

  2024cites this paper
• Systemic Immunological Changes After Yttrium-90 Radioembolization: A Pilot Prospective Observational Study—Clinical Insights

  2024cites this paper
• Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy.

  2024cites this paper
• Immune Effects of Intra-Arterial Liver-Directed Therapies.

  2024cites this paper
• Immune checkpoint inhibition: a future guided by radiology

  2023cites this paper
• Cancer Immunology: Impact of Radioembolization of Heptocellular Carcinoma on Immune Response Modulation.

  2023cites this paper
• Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions

  2023cites this paper
• Diagnostic and Prognostic Value of IL-10, FABP2 and LPS Levels in HCC Patients

  2023cites this paper
• Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape

  2023cites this paper
• A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence

  2023cites this paper
• The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma

  2023cites this paper
• Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

  2022cites this paper
• Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

  2022cites this paper
• Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.

  2021cites this paper
• Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy

  2021cites this paper
• 1 Pre-treatment sTNFR1 and HGF levels predict toxicity and overall survival after 90 Y radioembolization: potential novel application of biomarkers for personalized management of hepatotoxicity

  2021cites this paper
• Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

  2021cites this paper
• Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

  2021cites this paper
• Induction of contralateral hepatic hypertrophy by unilobar 90Y transarterial radioembolization vs. portal vein embolization: an animal study.

  2021cites this paper
• Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity

  2021cites this paper
• Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC

  2021cites this paper
• The evolution of interventional oncology in the 21st century.

  2020cites this paper
• Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy

  2020cites this paper
• Developments in predictive biomarkers for hepatocellular carcinoma therapy

  2020cites this paper
• Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres.

  2020cites this paper
• Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

  2019cites this paper
• Combined locoregional-immunotherapy for liver cancer.

  2019cites this paper
• Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver

  2019cites this paper
• Impact of Baseline Cholinesterase in Patients with Primary Liver Tumors Undergoing Radioembolization: Impact on Outcome

  2018cites this paper
• Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma

  2017cites this paper